Pfizer

Pfizer’s ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma

29 Apr 2026

Primary endpoint met at the interim analysis in MagnetisMM-5 trial demonstrating a statistically significant and clinically meaningful improvement in progression-free survival Safety was consistent wi

Pfizer Reaches Three Settlement Agreements for VYNDAMAX

28 Apr 2026

Pfizer Inc. (NYSE: PFE) today announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regarding lawsuits filed in t

Pfizer Announces 2026 Shareholder Meeting Preliminary Results

24 Apr 2026

NEW YORK, April 23, 2026 – Pfizer Inc. (NYSE: PFE) today held its Annual Meeting of Shareholders. Preliminary results from the Annual Meeting indicate that the shareholders: reelected the company’s 12

Pfizer Declares Second-Quarter 2026 Dividend

24 Apr 2026

Board of Directors approves quarterly cash dividend of $0.43 per share Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 second-quarter 2026 dividend on the company’

Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026

22 Apr 2026

New evidence for established standard-of-care therapies, with updates for LORBRENA® in ALK-positive metastatic non ‑ small cell lung cancer and a BRAFTOVI® regimen in a type of BRAF-mutant colorectal

U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

20 Apr 2026

Placeholder.

Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders

15 Apr 2026

Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual 2026 Annual Meeting of Shareholders on Thursday, April 23, 2026, at 9:00 a.m. EDT

Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts

24 Mar 2026

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, May 5, 2026. The purpose of

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

23 Mar 2026

Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above The investigational vaccine candidate was well tolerated wi

Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

23 Mar 2026

Pfizer Inc. (NYSE: PFE) today announced that it has received notice of an unsolicited mini-tender offer by Tutanota LLC (“Tutanota”) to purchase up to 1 million shares of Pfizer common stock at a pric

View details about the software product Informachine News Trackers